Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Suffolk, one of the most innovative and successful builders in the country, recently joined Gilead Sciences to celebrate the completion of its new Research Center in Foster City, California. Through close collaboration with Gilead, Suffolk delivered a highly specialized and adaptable research environment designed to evolve alongside the company's scientific needs, creating laboratory spaces that can accommodate new research teams, equipment and technologies.
Gilead Sciences NASDAQ: GILD expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Dickinson said at an investor conference.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead's existing voluntary licensing ag.
Selling shares in a down market can lock in losses just when retirees need cash most. Four dividend payers from telecom, asset management, biopharma and pizza offer another route, though one of them already cut its payout once.